Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Biogen to Keep Its Focus on High Unmet Needs, Win-Win Partnerships: CEO
January 31, 2017
- Latuda OK’ed in US for Adolescent Schizophrenia
January 31, 2017
- Mochida Filed Enbrel Biosimilar in Japan in October-December
January 31, 2017
- Linzess Delivers Positive Japan PIII Data in Chronic Constipation: Astellas
January 31, 2017
- Nippon Chemiphar, Nagase Medicals Win Elplat Patent Suit
January 30, 2017
- Mitsubishi Tanabe, Biogen Terminate MS Licensing Deal
January 30, 2017
- SBI to Initiate UK PII Study of 5-ALA for Prevention of Postoperative Cardiac Output Reduction
January 30, 2017
- Shionogi to Seek Expansion of Pediatric Indication for Sublingual Allergen Immunotherapy Tablet Actair
January 30, 2017
- Chugai to Shuffle Sales Organization to Cater to Community-Based Care
January 27, 2017
- Mochida Will Groom Lialda into Flagship Quickly: President
January 27, 2017
- Daiichi Sankyo Espha to Launch Micardis AG, Will Actively Handle Competitors’ Products
January 27, 2017
- Sumitomo Dainippon Completes Tolero Acquisition
January 27, 2017
- Lenvima Shows Non-Inferiority vs Nexavar in OS as Liver Cancer 1st Line Treatment
January 27, 2017
- Pfizer Adjusts Shipments for Tazopipe, Voluntarily Recalls Metformin Generics
January 27, 2017
- Biogen Japan to Make New Start as MS Powerhouse after Hemophilia Spin-off
January 25, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Takara Bio to Initiate PI/II Trial of Gene Therapy for Synovial Sarcoma
January 25, 2017
- Rohto Anticipates Large-Scale Stem Cell Production Using Automated System, Will Submit Clinical Trial Plan for Cirrhosis this Spring
January 25, 2017
- Napabucasin Add-On Shows Efficacy in Colorectal Cancer: Sumitomo Dainippon
January 24, 2017
- Takecab Most Heavily Pitched Drug in HP Market in November: Anterio
January 24, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…